Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer

Locally advanced breast cancer (LABC) cases have a varying five-year survival rate, mainly influenced by the tumor response to chemotherapy. Paclitaxel activity (response rate) varies across populations from 21.5% to 84%. There are some reports on genetic traits and paclitaxel; however, there is sti...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Perez-Ortiz, Andric C., Ramírez, Israel, Cruz-López, Juan C., Villarreal-Garza, Cynthia, Luna-Angulo, Alexandra, Lira-Romero, Esmeralda, Jiménez-Chaidez, Salvador, Díaz-Chávez, José, Matus-Santos, Juan A., Sánchez-Chapul, Laura, Mendoza-Lorenzo, Patricia, Estrada-Mena, Francisco J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739747/
https://ncbi.nlm.nih.gov/pubmed/29290962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22461
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg